The National Committee for Quality Assurance (NCQA) has announced a significant shift in how health plan performance regarding asthma care will be measured, signaling a move toward more clinical, outcome-oriented oversight. For the 2026 measurement year, the NCQA has officially retired the Asthma Medication Ratio (AMR), a long-standing Healthcare Effectiveness Data and Information Set (HEDIS) measure that evaluated the proportion of controller medications to total asthma medications dispensed to patients. In its place, the NCQA is elevating the "Follow-Up After Acute and Urgent Care Visits for Asthma" (AAF-E) measure. This transition marks a fundamental change in philosophy, moving away from a reliance on pharmacy claims as a proxy for disease management and toward a direct assessment of clinical intervention following a health crisis.
The retirement of the AMR measure addresses a long-standing criticism within the pulmonology and primary care communities. The AMR was designed to identify patients with persistent asthma by looking at utilization and dispensing patterns. However, medical experts have noted that this proxy frequently missed a significant segment of the patient population: those with intermittent asthma. While these patients may not require daily controller medications under standard guidelines, they remain at high risk for sudden, severe exacerbations. A patient can carry a diagnosis of intermittent asthma and still experience a life-threatening event that results in an emergency department (ED) visit. By retiring the AMR, the NCQA acknowledges that medication ratios alone are an insufficient indicator of comprehensive asthma control across the entire spectrum of the disease.
The Evolution of Asthma Quality Metrics: A Chronology of Change
The journey toward the 2026 HEDIS updates has been informed by years of clinical data suggesting that the "revolving door" of emergency asthma care is a primary driver of both poor patient outcomes and escalating healthcare costs. For over a decade, HEDIS measures focused heavily on medication adherence. The AMR was introduced to ensure that patients with persistent asthma were receiving the inhaled corticosteroids necessary to prevent inflammation. While effective in increasing awareness of controller therapy, the measure was limited by its reliance on administrative data—specifically, whether a prescription was filled, rather than whether the patient was clinically stable or possessed the skills to manage their condition.
In 2020, the National Asthma Education and Prevention Program (NAEPP) released its first major guideline update in over a decade, emphasizing "SMART" therapy (Single Maintenance and Reliever Therapy) and the importance of environmental trigger mitigation. Following these clinical updates, the NCQA began a multi-year review of its asthma suite. In 2022, the NCQA published a white paper highlighting that 42.4% of people with asthma had experienced at least one exacerbation in the previous year, despite the prevalence of the AMR measure. This data suggested a "quality gap" where patients were filling prescriptions but still failing to avoid acute crises.
By 2024, the NCQA finalized the AAF-E measure, transitioning it to an Electronic Clinical Quality Measure (eCQM) format. This allows for more nuanced data collection from electronic health records (EHRs) rather than just insurance claims. The implementation for the 2026 measurement year represents the culmination of this transition, forcing health plans and providers to prioritize the critical 30-day window following an acute event.
Understanding the New AAF-E Measure
The replacement measure, Follow-Up After Acute and Urgent Care Visits for Asthma (AAF-E), tracks the percentage of patients aged 5 to 64 who were treated in an urgent care center, emergency department, or admitted for an inpatient or observation stay due to asthma, and who subsequently received a follow-up visit with an asthma diagnosis within 30 days of discharge.
The scope of this measure is significantly broader than its predecessor. It captures a wider age range and focuses on the point of highest risk. The NCQA’s rationale is rooted in the "post-acute" period—the month following an ED visit—which is statistically the time a patient is most likely to suffer a relapse. The measure is designed to ensure that the healthcare system "closes the loop" by bringing the patient back into a primary or specialty care setting to adjust their long-term management plan.
However, clinical analysts point to a potential "process vs. quality" gap within the new metric. While the AAF-E measure requires a follow-up visit to occur, it does not currently mandate specific clinical outcomes within that visit. The NCQA’s description of the measure suggests that the visit should involve checking symptom resolution, assessing lung function via spirometry, and identifying triggers. Yet, for the purposes of HEDIS reporting, the simple presence of a claim with an asthma diagnosis code within the 30-day window satisfies the requirement. This has led industry leaders to urge practices to look beyond the "checkbox" and focus on the substantive quality of the encounter.

Supporting Data: The High Stakes of Post-Acute Care
The need for this shift is underscored by alarming statistics regarding asthma morbidity in the United States. In 2020, asthma accounted for nearly one million emergency department visits. An NCQA claims analysis revealed a startling deficiency in follow-up care: less than half of asthma-related ED visits were followed by an outpatient appointment within 30 days. The disparity is even more pronounced across different insurance types. While commercial populations saw a 30-day follow-up rate of 46.1%, the rate dropped to just 33.9% for Medicaid populations.
These figures represent a significant missed opportunity for intervention. Research indicates that a recent exacerbation is the single strongest predictor of future respiratory failure. In a large U.S. cohort study of patients with severe or difficult-to-treat asthma, those aged 12 and older who had an ED visit or hospitalization in the prior three months had more than six times the odds of experiencing another severe exacerbation within the following 18 months.
In pediatric populations, the statistics are even more dire. A systematic review of six studies involving more than 162,000 children found that the odds of a repeat exacerbation increased nearly tenfold after an initial event. Despite this, a study of 90,000 pediatric ED visits showed that follow-up within 14 days only reduced return visits from 28.3% to 25%. This modest improvement suggests that while the timing of the visit matters, the content of the visit is what truly determines long-term stability.
Clinical Implications: What Constitutes a Successful Follow-Up?
To move the needle on asthma outcomes, clinicians are being encouraged to move beyond simple medication refills during the 30-day follow-up window. A comprehensive post-acute visit should address several critical pillars of asthma management:
- Validated Control Assessment: Rather than asking a patient if they "feel okay," clinicians are urged to use validated tools like the Asthma Control Test (ACT). These tools provide a numerical score that can objectively track improvements or declines in stability over time.
- Inhaler Technique Verification: Data shows that medication adherence is often undermined by poor delivery. A systematic review of 144 studies found that only 31% of patients with asthma or COPD used correct inhaler technique—a statistic that has remained stagnant for decades. Without a physical demonstration during the follow-up visit, a clinician may incorrectly assume a medication is ineffective when the issue is actually mechanical.
- Root Cause Analysis: The follow-up visit is the ideal time to investigate the "why" behind the ED visit. This includes discussing environmental exposures, such as new pets, mold, or workplace chemicals, as well as behavioral factors like smoking or vaping.
- Diagnostic Clarification: For many older adults, a follow-up visit provides an opportunity to reassess the diagnosis itself. Studies suggest that 25% to 50% of patients labeled with COPD may actually have untreated asthma or Asthma-COPD Overlap Syndrome (ACOS). Correctly identifying the underlying pathology is essential for choosing the right biologic or inhaled therapy.
Official Responses and Industry Reactions
While the NCQA has not released formal statements from individual health plans, provider guidance documents from organizations like SelectHealth indicate that the industry is already preparing for the 2026 deadline. Many plans are recommending that the follow-up visit be scheduled before the patient even leaves the hospital or ED. Some are even pushing for a tighter window of 7 to 14 days, rather than the 30 days allowed by the HEDIS measure.
Telehealth providers have also responded positively to the change. Since the AAF-E measure allows for telehealth visits to count toward the metric, virtual care platforms are being integrated into discharge workflows to ensure rapid access to a provider. However, professional societies, including the American Academy of Allergy, Asthma & Immunology (AAAAI), have cautioned that while telehealth improves access, it may limit the ability to perform necessary physical tests like spirometry or observe inhaler technique in person.
Broader Impact and Economic Implications
The economic burden of asthma is driven primarily by repeat, high-acuity events. A 2025 study of nearly 90,000 working-age asthma patients found that the frequency of exacerbations is the primary driver of healthcare spending. By shifting the HEDIS focus to the post-acute follow-up, the NCQA is incentivizing a preventative model that could save the healthcare system billions of dollars.
The "Inner-City Asthma Study" demonstrated that when follow-up care includes tailored interventions—such as home visits to reduce allergen exposure—symptom days are significantly reduced. Though these interventions carry an upfront cost (approximately $1,469 per family), the subsequent reduction in unscheduled clinic and ED visits results in a net positive return on investment.
As the 2026 measurement year approaches, the transition from the Asthma Medication Ratio to the Follow-Up After Acute and Urgent Care Visits for Asthma measure represents a maturing of healthcare quality standards. It moves the conversation from "did the patient get their medicine?" to "did the system care for the patient when they were most vulnerable?" The true success of this change will not be measured by the number of claims filed, but by whether the 30-day visit can successfully break the cycle of repeat exacerbations that has plagued asthma care for generations.
